医学
四分位间距
溶栓
改良兰金量表
冲程(发动机)
纤溶剂
组织纤溶酶原激活剂
外科
内科学
麻醉
缺血性中风
缺血
心肌梗塞
机械工程
工程类
作者
Timo Kahles,Marie‐Luise Mono,Mirjam R. Heldner,Ralf Werner Baumgartner,Hakan Sarıkaya,Andreas Rüdiger Luft,Stephan Bohlhalter,Christopher Traenka,Stefan T. Engelter,Natalia Kurka,Martin Köhrmann,Sami Curtze,Patrik Michel,Turgut Tatlisumak,Krassen Nedeltchev
出处
期刊:Stroke
[Lippincott Williams & Wilkins]
日期:2016-07-01
卷期号:47 (8): 2133-2135
被引量:32
标识
DOI:10.1161/strokeaha.116.013599
摘要
BACKGROUND AND PURPOSE: Intravenous thrombolysis (IVT) within 4.5 hours from symptom onset improves functional outcome in patients with acute ischemic stroke. Its use in patients with previous stroke within the preceding 3 months is contraindicated because of the assumed higher risk of intracranial hemorrhage. In addition, tissue-type plasminogen activator may itself promote neurotoxicity and blood-brain barrier disruption. However, safety and effectiveness of repeated IVT is essentially unknown in patients with early (<3 months) recurrent stroke (ERS), because they were excluded from thrombolysis trials. This article reports the largest case series of repeated IVT in ERS. METHODS: We reviewed databases of prospectively collected patient data of 8 European stroke centers for the presence of patients with ERS, who received IVT for both the index stroke and ERS. Demographics, clinical and radiological data, bleeding complications, and functional outcome were analyzed. RESULTS: We identified 19 subjects with repeated IVT in ERS. Mean age was 68±12 years, and 37% of them were female. Median interthrombolysis interval was 30 days (interquartile range, 13-50). Functional independence (modified Rankin scale score ≤2) was achieved in 79% of patients after the first and in 47.4% after repeated IV tissue-type plasminogen activator, respectively. There was no symptomatic intracranial hemorrhage. Median final infarct volume after the first IVT was 1.5 cm(3) (interquartile range, 0.5-3.1). CONCLUSIONS: Patients with small infarct volumes and robust clinical improvement might be considered for repeated IVT within 3 months. Studies following strict protocols and larger registries incorporating these patients might serve to identify selection criteria for the safe use of repeated IVT in ERS.
科研通智能强力驱动
Strongly Powered by AbleSci AI